Communiqués Deciphera Pharmaceuticals, Inc.

Actions

DCPH

US24344T1016

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
25,59 ^USD	+0,08%		-.--%	-

17/06	Deciphera Pharmaceuticals administre la première dose dans l'étude pivot de phase 3 INTREPID sur le sapablursen dans la maladie de Vaquez	CI
26/03	Ono Pharmaceutical dépose une demande d'homologation pour le ripretinib au Japon	CI

Communiqués

03/06/24	Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet	BU
02/05/24	DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH	BU
29/04/24	Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion	BU
09/04/24	Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	BU
27/02/24	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
06/02/24	Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results	BU
01/02/24	Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024	BU
01/02/24	Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	BU
18/01/24	Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	BU
10/01/24	GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe	AQ
08/01/24	Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company	BU
05/01/24	Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	BU
02/01/24	Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	BU
29/11/23	Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit	BU
07/11/23	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
31/10/23	Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT	AQ
30/10/23	Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results	BU
30/10/23	Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT	BU
25/10/23	EUCOPE Member Spotlight, Q&A with Deciphera	AQ
29/09/23	Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment	AQ
15/09/23	Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
21/08/23	Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
18/08/23	Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
09/08/23	Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results	BU
03/08/23	Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer	BU